News

Healio13d
FDA fast tracks urcosimod for neuropathic corneal pain
The FDA granted fast track designation to urcosimod to treat neuropathic corneal pain, according to a press release from Okyo Pharma. Urcosimod, formerly called OK-101, is a “lipid conjugated chemerin ...
Ophthalmology Times12d
FDA grants fast track designation to OKYO Pharma’s urcosimod for treatment of neuropathic corneal pain
NCP is a condition that causes severe pain and sensitivity of the eyes, face, or head. The exact cause is unknown but is ...
Investing14d
OKYO Pharma speeds up NCP drug development
a drug candidate aimed at treating Neuropathic Corneal Pain (NCP). The company’s stock has shown remarkable momentum, gaining over 34% in the past six months, according to InvestingPro data.
The Manila Times13d
FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain
OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod ...
Investing14d
OKYO Pharma speeds up NCP drug development
a drug candidate aimed at treating Neuropathic Corneal Pain (NCP). The company’s stock has shown remarkable momentum, gaining over 34% in the past six months, according to InvestingPro data. The trial ...